Plasma desacyl ghrelin‑to‑acyl ghrelin ratio is a predictor of postoperative complications and prognosis after pancreaticoduodenectomy

Nishida,Takahiro; Tsubouchi,Hironobu; Hamada,Takeomi; Imamura,Naoya; Hiyoshi,Masahide; Yano,Koichi; Kangawa,Kenji; Nakazato,Masamitsu; Nanashima,Atsushi

doi:10.3892/ol.2019.10821

Plasma desacyl ghrelin‑to‑acyl ghrelin ratio is a predictor of postoperative complications and prognosis after pancreaticoduodenectomy

Authors:
- Takahiro Nishida
- Hironobu Tsubouchi
- Takeomi Hamada
- Naoya Imamura
- Masahide Hiyoshi
- Koichi Yano
- Kenji Kangawa
- Masamitsu Nakazato
- Atsushi Nanashima
View Affiliations

Affiliations: Division of Gastrointestinal, Endocrine and Pediatric Surgery, Department of Surgery, University of Miyazaki Faculty of Medicine, Miyazaki 889‑1692, Japan, Division of Neurology, Respirology, Endocrinology and Metabolism, Department of Internal Medicine, University of Miyazaki Faculty of Medicine, Miyazaki 889‑1692, Japan, Division of Hepato‑Biliary‑Pancreatic Surgery, Department of Surgery, University of Miyazaki Faculty of Medicine, Miyazaki 889‑1692, Japan, Department of Biochemistry, National Cardiovascular Center Research Institute, Osaka 565‑8565, Japan
Published online on: September 6, 2019 https://doi.org/10.3892/ol.2019.10821
Pages: 4974-4983

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The current study aimed to clarify the significance of the preoperative desacyl ghrelin (DG)‑to‑acyl ghrelin (AG) ratio in patients undergoing pancreaticoduodenectomy (PD). Ghrelin, a peptide hormone mainly produced in the stomach, possesses unique functions. Recently, studies have determined the involvement of plasma gherlin in certain postoperative outcomes, particularly in surgical resections of the stomach. Although PD involves gastric resection, few reports have determined the involvement of ghrelin following PD. From April 2003 to December 2011, 195 patients underwent PD for tumors of the pancreatic head, bile duct and ampulla of Vater at the Division of Hepato‑Biliary‑Pancreatic Surgery, Department of Surgery, University of Miyazaki Faculty of Medicine (Miyazaki, Japan). Of these, 83 patients were enrolled into the present study as their plasma gherlin levels were measured. AG, DG, total ghrelin (TG) and the DG‑to‑AG ratio (D/A) were subsequently assessed. Furthermore, the prognostic nutritional index (PNI) and high‑sensitivity modified Glasgow Prognostic Score (HS‑mGPS) were determined. Morbidity was examined in all 83 patients, but mortality was only determined in 69 individuals after 14 patients were excluded due to the presence of benign disease. The results revealed that the TG of patients undergoing standard PD (SPD) was significantly lower than that of patients undergoing pylorus‑preserving PD or subtotal stomach‑preserving PD. It was also determined that TG levels declined significantly in SPD patients at 2 weeks after surgery. Negative associations were identified between plasma ghrelin levels and PNI, and between serum albumin and HS‑mGPS. Patient morbidity was determined to be 31.3% and the severe complications exhibited by patients included pancreatic fistula (14.5%), intra‑abdominal abscess (15.7%), intra‑abdominal bleeding (6.0%) and liver abscess (1.2%). Multivariate analysis revealed that disease location and low D/A were independent risk factors for severe complications. The 5‑year overall survival (OS) rate was 41.5%. Multivariate analysis also demonstrated that diabetes mellitus, long postoperative hospital stay and low D/A were independent risk factors for OS. The present study revealed the D/A may serve as a useful predictive factor for postoperative complications and prognosis after PD.

View Figures

View References

1	Diener MK, Knaebel HP, Heukaufer C, Antes G, Büchler MW and Seiler CM: A systematic review and meta-analysis of pylorus-preserving versus classical pancreaticoduodenectomy for surgical treatment of periampullary and pancreatic carcinoma. Ann Surg. 245:187–200. 2007. View Article : Google Scholar : PubMed/NCBI
2	Huang W, Xiong JJ, Wan MH, Szatmary P, Bharucha S, Gomatos I, Nunes QM, Xia Q, Sutton R and Liu XB: Meta-analysis of subtotal stomach-preserving pancreaticoduodenectomy vs. pylorus preserving pancreaticoduodenectomy. World J Gastroenterol. 21:6361–6373. 2015. View Article : Google Scholar : PubMed/NCBI
3	Watson K: Carcinoma of ampulla of vater successful radical resection. Br J Surg. 31:368–373. 1944. View Article : Google Scholar
4	Traverso LW and Longmire WJ: Preservation of the pylorus in pancreaticoduodenectomy. Surg Gynecol Obstet. 146:959–962. 1978.PubMed/NCBI
5	Hiyoshi M, Chijiiwa K, Ohuchida J, Imamura N and Nagano M: Comparative study of gastric emptying and nutritional status after pylorus-preserving vs. subtotal stomach-preserving pancreaticoduodenectomy. Hepatogastroenterology. 59:1018–1022. 2012.PubMed/NCBI
6	Zhao R, Chang Y, Wang X, Zhang P, Zhang C and Lian P: Pylorus-preserving pancreaticoduodenectomy versus standard pancreaticoduodenectomy in the treatment of duodenal papilla carcinoma. Oncol Lett. 15:6368–6376. 2018.PubMed/NCBI
7	Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H and Kangawa K: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 402:656–660. 1999. View Article : Google Scholar : PubMed/NCBI
8	Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, Ueno N, Makino S, Fujimiya M, Niijima A, Fujino MA and Kasuga M: Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology. 120:337–345. 2001. View Article : Google Scholar : PubMed/NCBI
9	Muccioli G, Tschöp M, Papotti M, Deghenghi R, Heiman M and Ghigo E: Neuroendocrine and peripheral activities of ghrelin: Implications in metabolism and obesity. Eur J Pharmacol. 440:235–254. 2002. View Article : Google Scholar : PubMed/NCBI
10	Takachi K, Doki Y, Ishikawa O, Miyashiro I, Sasaki Y, Ohigashi H, Murata K, Nakajima H, Hosoda H, Kangawa K, et al: Postoperative ghrelin levels and delayed recovery from body weight loss after distal or total gastrectomy. J Surg Res. 130:1–7. 2006. View Article : Google Scholar : PubMed/NCBI
11	Doki Y, Takachi K, Ishikawa O, Miyashiro I, Sasaki Y, Ohigashi H, Nakajima H, Hosoda H, Kangawa K, Sasakuma F, et al: Ghrelin reduction after esophageal substitution and its correlation to postoperative body weight loss in esophageal cancer patients. Surgery. 139:797–805. 2006. View Article : Google Scholar : PubMed/NCBI
12	Takiguchi S, Murakami K, Yanagimoto Y, Takata A, Miyazaki Y, Mori M and Doki Y: Clinical application of ghrelin in the field of surgery. Surg Today. 45:801–807. 2015. View Article : Google Scholar : PubMed/NCBI
13	Tsuchimochi W, Kyoraku I, Yamaguchi H, Toshinai K, Shiomi K, Kangawa K and Nakazato M: Ghrelin prevents the development of experimental diabetic neuropathy in rodents. Eur J Pharmacol. 702:187–193. 2013. View Article : Google Scholar : PubMed/NCBI
14	Yano Y, Nakazato M, Toshinai K, Inokuchi T, Matsuda S, Hidaka T, Hayakawa M, Kangawa K, Shimada K and Kario K: Circulating des-acyl ghrelin improves cardiovascular risk prediction in older hypertensive patients. Am J Hypertens. 27:727–733. 2014. View Article : Google Scholar : PubMed/NCBI
15	Kanda M, Fujii T, Kodera Y, Nagai S, Takeda S and Nakao A: Nutritional predictors of postoperative outcome in pancreatic cancer. Br J Surg. 98:268–274. 2011. View Article : Google Scholar : PubMed/NCBI
16	Zhang P, Xi M, Li QQ, He LR, Liu SL, Zhao L, Shen JX and Liu MZ: The modified glasgow prognostic score is an independent prognostic factor in patients with inoperable thoracic esophageal squamous cell carcinoma undergoing chemoradiotherapy. J Cancer. 5:689–695. 2014. View Article : Google Scholar : PubMed/NCBI
17	Chen P, Fang M, Wan Q, Zhang X, Song T and Wu S: High-sensitivity modified Glasgow prognostic score (HS-mGPS) is superior to the mGPS in esophageal cancer patients treated with chemoradiotherapy. Oncotarget. 8:99861–99870. 2017.PubMed/NCBI
18	Cui Y, Li J, Cao YH, Liu MY, Shi ZX and Gao TH: Predictive and prognostic significance of high-sensitivity modified glasgow prognostic score (HS-mGPS) in advanced gastric cancer patients treated with neoadjuvant chemotherapy. Zhonghua Zhong Liu Za Zhi. 39:195–200. 2017.(In Chinese). PubMed/NCBI
19	Brierley JD, Gospodarowicz MK and Wittekind C: TNM classification of malignant tumors8th. Wiley-Blackwell; 2017
20	Dindo D, Demartines N and Clavien PA: Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 240:205–213. 2004. View Article : Google Scholar : PubMed/NCBI
21	Hiyoshi M, Chijiiwa K, Fujii Y, Imamura N, Nagano M and Ohuchida J: Usefulness of drain amylase, serum C-reactive protein levels and body temperature to predict postoperative pancreatic fistula after pancreaticoduodenectomy. World J Surg. 37:2436–2442. 2013. View Article : Google Scholar : PubMed/NCBI
22	Kakita A, Yoshida M and Takahashi T: History of pancreaticojejunostomy in pancreaticoduodenectomy: Development of a more reliable anastomosis technique. J Hepatobiliary Pancreat Surg. 8:230–237. 2001. View Article : Google Scholar : PubMed/NCBI
23	Chijiiwa K, Imamura N, Ohuchida J, Hiyoshi M, Nagano M, Otani K, Kai M and Kondo K: Prospective randomized controlled study of gastric emptying assessed by (13)C-acetate breath test after pylorus-preserving pancreaticoduodenectomy: Comparison between antecolic and vertical retrocolic duodenojejunostomy. J Hepatobiliary Pancreat Surg. 16:49–55. 2009. View Article : Google Scholar : PubMed/NCBI
24	Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, Kaneoka Y, Shimizu Y, Nakamori S, Sakamoto H, et al: Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: A phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 388:248–257. 2016. View Article : Google Scholar : PubMed/NCBI
25	Nanashima A, Murakami G, Takagi K, Arai J, Sumida Y, Kodama T and Nagayasu T: Relationship between serum ghrelin level and physiology in patients who underwent hepatectomy and pancreatectomy. Acta Med Nagasaki. 61:55–60. 2017.
26	Sasaki K, Asaoka T, Eguchi H, Fukuda Y, Iwagami Y, Yamada D, Miyazaki Y, Noda T, Takahashi T, Gotoh K, et al: Plasma ghrelin suppression as an early predictor for postoperative complications after pancreatoduodenectomy. Pancreatology. 18:73–78. 2018. View Article : Google Scholar : PubMed/NCBI
27	Takiguchi S, Takata A, Murakami K, Miyazaki Y, Yanagimoto Y, Kurokawa Y, Takahashi T, Mori M and Doki Y: Clinical application of ghrelin administration for gastric cancer patients undergoing gastrectomy. Gastric Cancer. 17:200–205. 2014. View Article : Google Scholar : PubMed/NCBI
28	Kasai C, Sugimoto K, Moritani I, Tanaka J, Oya Y, Inoue H, Tameda M, Shiraki K, Ito M, Takei Y and Takase K: Changes in plasma ghrelin and leptin levels in patients with peptic ulcer and gastritis following eradication of Helicobacter pylori infection. BMC Gastroenterol. 16:1192016. View Article : Google Scholar : PubMed/NCBI
29	Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal MS, Tanaka M, Nozoe S, Hosoda H, Kangawa K and Matsukura S: Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab. 87:240–244. 2002. View Article : Google Scholar : PubMed/NCBI
30	Date Y, Murakami N, Toshinai K, Matsukura S, Niijima A, Matsuo H, Kangawa K and Nakazato M: The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology. 123:1120–1128. 2002. View Article : Google Scholar : PubMed/NCBI
31	Kumamoto Y, Kaizu T, Tajima H, Nishizawa N, Ei S, Igarashi K and Watanabe M: Neutrophil-to-lymphocyte ratio as a predictor of postoperative morbidity in patients with distal cholangiocarcinoma. Mol Clin Oncol. 9:362–368. 2018.PubMed/NCBI
32	Duxbury MS, Waseem T, Ito H, Robinson MK, Zinner MJ, Ashley SW and Whang EE: Ghrelin promotes pancreatic adenocarcinoma cellular proliferation and invasiveness. Biochem Biophys Res Commun. 309:464–468. 2003. View Article : Google Scholar : PubMed/NCBI
33	Jeffery PL, Murray RE, Yeh AH, McNamara JF, Duncan RP, Francis GD, Herington AC and Chopin LK: Expression and function of the ghrelin axis, including a novel preproghrelin isoform, in human breast cancer tissues and cell lines. Endocr Relat Cancer. 12:839–850. 2005. View Article : Google Scholar : PubMed/NCBI
34	Lin TC, Liu YP, Chan YC, Su CY, Lin YF, Hsu SL, Yang CS and Hsiao M: Ghrelin promotes renal cell carcinoma metastasis via Snail activation and is associated with poor prognosis. J Pathol. 237:50–61. 2015. View Article : Google Scholar : PubMed/NCBI
35	Waseem T, Javaid-Ur-Rehman, Ahmad F, Azam M and Qureshi MA: Role of ghrelin axis in colorectal cancer: A novel association. Peptides. 29:1369–1376. 2008. View Article : Google Scholar : PubMed/NCBI
36	Lin TC and Hsiao M: Ghrelin and cancer progression. Biochim Biophys Acta Rev Cancer. 1868:51–57. 2017. View Article : Google Scholar : PubMed/NCBI
37	Yanagi S, Sato T, Kangawa K and Nakazato M: The homeostatic force of ghrelin. Cell Metab. 27:786–804. 2018. View Article : Google Scholar : PubMed/NCBI
38	Zeng X, Chen S, Lin Y and Ke Z: Acylated and unacylated ghrelin inhibit apoptosis in myoblasts cocultured with colon carcinoma cells. Oncol Rep. 39:1387–1395. 2018.PubMed/NCBI
39	Garcia JM, Garcia-Touza M, Hijazi RA, Taffet G, Epner D, Mann D, Smith RG, Cunningham GR and Marcelli M: Active ghrelin levels and active to total ghrelin ratio in cancer-induced cachexia. J Clin Endocrinol Metab. 90:2920–2926. 2005. View Article : Google Scholar : PubMed/NCBI
40	Kerem M, Ferahkose Z, Yilmaz UT, Pasaoglu H, Ofluoglu E, Bedirli A, Salman B, Sahin TT and Akin M: Adipokines and ghrelin in gastric cancer cachexia. World J Gastroenterol. 14:3633–3641. 2008. View Article : Google Scholar : PubMed/NCBI
41	Ozola Zalite I, Zykus R, Francisco Gonzalez M, Saygili F, Pukitis A, Gaujoux S, Charnley RM and Lyadov V: Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: A systematic review. Pancreatology. 15:19–24. 2015. View Article : Google Scholar : PubMed/NCBI
42	Abe K, Uwagawa T, Haruki K, Takano Y, Onda S, Sakamoto T, Gocho T and Yanaga K: Effects of ω-3 fatty acid supplementation in patients with bile duct or pancreatic cancer undergoing chemotherapy. Anticancer Res. 38:2369–2375. 2018.PubMed/NCBI